Zheng Quan Shi Bao Wang·2025-09-30 00:53Core Viewpoint - 麦科奥特 has submitted a listing application to the Hong Kong Stock Exchange, with CCB International and China Merchants Securities International as joint sponsors, focusing on developing next-generation bispecific/multispecific peptide drugs for metabolic diseases, particularly kidney-related and cardiovascular diseases [1] Group 1: Product Development - The core product MT1013 is a dual-target receptor agonist peptide drug for treating secondary hyperparathyroidism (SHPT), which has completed Phase II clinical trials and is now entering Phase III trials [1] - MT1013's Phase II clinical trial results show promising outcomes in improving iPTH/blood calcium/phosphorus target rates, reducing iPTH, increasing bone density, and enhancing bone metabolism, with potential cardiovascular benefits [1] Group 2: Pipeline and Future Prospects - Another key product, XTL6001, is the world's first GLP-1R/GCGR/MasR triple-target agonist to enter clinical trials in both China and the United States, showing potential for treating obesity, chronic kidney disease, and fatty liver disease [1] - The company is advancing three additional candidate products that are currently in clinical stages [1]